According to a whistleblower complaint, in September 2018, Michael Mullen of National Securities Corporation (NSC) allegedly engaged in insider trading of stocks of TG Therapeutics—a subsidiary of NSC’s parent company Fortress Biotech, Inc—days before the biopharmaceutical company announced the disappointing results of their clinical trials for “U2,” a potential treatment for chronic lymphocytic leukemia. According…

Read More